NBY vs. FGEN, BRNS, STTK, RLMD, NBRV, ANVS, TPST, ATHE, JSPR, and AADI
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include FibroGen (FGEN), Barinthus Biotherapeutics (BRNS), Shattuck Labs (STTK), Relmada Therapeutics (RLMD), Nabriva Therapeutics (NBRV), Annovis Bio (ANVS), Tempest Therapeutics (TPST), Alterity Therapeutics (ATHE), Jasper Therapeutics (JSPR), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.
NovaBay Pharmaceuticals vs. Its Competitors
FibroGen (NASDAQ:FGEN) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
FibroGen currently has a consensus target price of $43.00, suggesting a potential upside of 257.44%. NovaBay Pharmaceuticals has a consensus target price of $0.85, suggesting a potential downside of 67.18%. Given FibroGen's higher probable upside, equities analysts clearly believe FibroGen is more favorable than NovaBay Pharmaceuticals.
FibroGen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
72.7% of FibroGen shares are owned by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 3.1% of FibroGen shares are owned by company insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
FibroGen has a net margin of -3.86% compared to NovaBay Pharmaceuticals' net margin of -102.72%. FibroGen's return on equity of 0.00% beat NovaBay Pharmaceuticals' return on equity.
In the previous week, FibroGen had 2 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 2 mentions for FibroGen and 0 mentions for NovaBay Pharmaceuticals. FibroGen's average media sentiment score of 0.14 beat NovaBay Pharmaceuticals' score of 0.00 indicating that FibroGen is being referred to more favorably in the media.
NovaBay Pharmaceuticals has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
FibroGen beats NovaBay Pharmaceuticals on 12 of the 15 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:NBY) was last updated on 9/14/2025 by MarketBeat.com Staff
Free NBY Stock Alerts